Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 2341 to 2355 of 9046 results

  1. MTEP - Routing Butterfly IQ ultrasound scanner MT635 (MIB254)

    Topic prioritisation

  2. Infection prevention and control update

    In development Reference number: GID-QS10177 Expected publication date: TBC

  3. Vacuum Assisted Excision for the removal of breast lesions of uncertain malignant potential

    Topic prioritisation

  4. Omental lymph node transfer for lymphoedema of the limbs

    Topic prioritisation

  5. MT658 Quit Genius for Smoking Cessation

    Topic prioritisation

  6. Denecimig (Mim8) for preventing bleeding episodes in haemophilia A in people of any age [ID6400]

    In development Reference number: GID-TA11509 Expected publication date:  24 February 2027

  7. Tezepelumab for treating severe chronic rhinosinusitis with nasal polyps [ID6379]

    In development Reference number: GID-TA11429 Expected publication date:  09 September 2026

  8. Tislelizumab with chemotherapy for untreated advanced oesophageal squamous cell cancer [ID5113]

    In development Reference number: GID-TA11025 Expected publication date:  10 February 2027

  9. Taselisib for previously treated ER-positive, HER2-negative, PIK3CA-positive breast cancer in postmenopausal women [ID1401]

    In development Reference number: GID-TA10326 Expected publication date: TBC

  10. Decitabine–cedazuridine with venetoclax for untreated acute myeloid leukaemia when intensive induction chemotherapy is unsuitable [ID6601]

    In development Reference number: GID-TA11765 Expected publication date: TBC

  11. Topical tapinarof for treating atopic dermatitis in people 2 years and over ID6713

    In development Reference number: GID-TA11952 Expected publication date: TBC

  12. Eplontersen for treating transthyretin-related amyloidosis cardiomyopathy [ID6759]

    Awaiting development Reference number: GID-TA11551 Expected publication date: TBC

  13. Orforglipron for managing overweight and obesity [ID6516]

    In development Reference number: GID-TA11650 Expected publication date:  18 November 2026

  14. Elinzanetant for treating vasomotor symptoms caused by adjuvant endocrine treatment to prevent or treat hormone-receptor positive breast cancer [ID6544]

    Awaiting development Reference number: GID-TA11784 Expected publication date: TBC

  15. Atrasentan for treating primary IgA nephropathy [ID6558]

    Awaiting development Reference number: GID-TA11756 Expected publication date: TBC